Zollinger-Ellison syndrome (ZES) is a disease entity which refers to the triad of severe peptic ulcer disease (PUD), gastric acid hypersecretion and non-beta cell gastrin-secreting tumor primarily of the pancreas and duodenum (gastrinoma).
Approximately two-thirds of patients have sporadic ZES while the rest is part of multiple endocrine neoplasia type 1.
ZES should be considered in the differential diagnoses of patients who present with abdominal pain, malabsorption and chronic watery diarrhea.
A high index of clinical awareness is necessary to correctly diagnose ZES.
Disease-free survival (DFS) at 3 years was comparable between patients with locally advanced gastric cancer who underwent laparoscopic distal gastrectomy and open distal gastrectomy, pointing to the noninferiority of the laparoscopic procedure to the open one, according to the CLASS-01* study.
Mortality, length of stay (LOS) and hospital charges are significantly higher in chronic liver disease (CLD) patients with fractures, a recent study has shown. These findings are also associated with increased infection, bleeding and poorer wound healing.
New drug applications approved by US FDA as of 16 - 30 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.